Pulmonary Embolism

On this page

Quick Reference

RxDrug of choiceApixaban (10 mg PO BID ×7 days, then 5 mg PO BID), lowest bleeding risk among DOACs (NNT=27 vs rivaroxaban).

AltAlternativesRivaroxaban (15 mg PO BID ×21 days, then 20 mg PO daily); Edoxaban (60 mg PO daily after 5 days of LMWH); LMWH (dalteparin 200 IU/kg SC daily) for cancer or pregnancy; Warfarin (INR 2-3) for antiphospholipid syndrome.

⊘AvoidDOACs in antiphospholipid syndrome (higher recurrence); DOACs in severe renal impairment (CrCl <15-30 mL/min depending on agent); DOACs in pregnancy and lactation; Systemic fibrinolysis in patients with active bleeding, recent major surgery, or intracranial pathology.

DxTest of choiceCT pulmonary angiography (CTPA), gold standard with 100% negative predictive value. V/Q scan as alternative when contrast is contraindicated.

ScKey scoreSimplified Pulmonary Embolism Severity Index (sPESI), score 0 identifies low-risk patients (30-day mortality ~1%). Bova score for intermediate-risk stratification (stages I-III with 4.2-29.2% complication rates).

→When to referRefer to interventional cardiology or radiology for catheter-directed fibrinolysis in intermediate-risk patients with cardiorespiratory distress; refer to pulmonary hypertension specialist for suspected CTEPH; refer to hematology for recurrent VTE or antiphospholipid syndrome.

Risk-stratify all patients with PE using hemodynamics, biomarkers, and RV imaging; initiate DOAC (apixaban preferred) immediately; escalate to reperfusion only for high-risk or selected intermediate-risk patients; manage low-risk patients as outpatients using Hestia criteria.

Pulmonary embolism (PE) is a common cardiovascular emergency caused by thrombotic obstruction of pulmonary arteries, often from lower extremity DVT. It is a leading cause of maternal mortality and requires prompt diagnosis and risk-stratified management. This bedside reference condenses key clinical facts, drug doses, critical thresholds, and evidence-based algorithms for acute and long-term care.

Overview and Recommendations

Background

•Pulmonary embolism (PE), obstruction of the pulmonary arteries by thrombus, usually from lower-extremity deep veins, is the third most frequent cardiovascular emergency worldwide and a leading cause of maternal mortality in the developed world, with an estimated 60,000-100,000 deaths annually in the United States alone.
•The paradigm for acute PE management shifted from a one-size-fits-all approach (heparin → warfarin) to a risk-stratified model driven by the 2014 ESC algorithm and the 2016 CHEST guideline, which established DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) as first-line over vitamin K antagonists, a change supported by the landmark EINSTEIN-PE, Hokusai-VTE, and AMPLIFY trials, which collectively showed comparable efficacy with 40-50% less major bleeding.
•The central pathophysiology is acute right ventricular (RV) pressure overload from mechanical obstruction and neurohumoral vasoconstriction (thromboxane A₂, serotonin). A thin-walled RV poorly adapted to sudden afterload dilates, becomes ischemic, and fails, the hallmark of high-risk (massive) PE. In a subset of patients, failure of clot lysis leads to chronic thromboembolic pulmonary hypertension (CTEPH), driven by plasmin-resistant fibrin and a macrophage-driven inflammatory milieu.
•PE is classified by clinical severity: high-risk (sustained hypotension SBP <90 mmHg for ≥15 min or requiring vasopressors), intermediate-risk (normotensive but with RV dysfunction on imaging or elevated cardiac biomarkers), and low-risk (no RV strain, normal biomarkers). The 30-day mortality ranges from <1% in low-risk patients managed as outpatients to 30-50% in high-risk PE with shock.

Evaluation

•Suspect PE in any patient with acute dyspnea, pleuritic chest pain, hemoptysis, or syncope, especially when accompanied by risk factors such as recent surgery, immobilization, cancer, pregnancy, or prior VTE.
•Assess pre-test probability using a validated tool, the simplified single-question approach ('Is PE the most likely diagnosis?') is as effective as the or and allows a higher D-dimer threshold of 1000 ng/mL when PE is not the most likely diagnosis.
•Order a high-sensitivity assay in patients with low or moderate pre-test probability. Use age-adjusted thresholds: for age ≥50 years, the upper limit of normal is age × 10 ng/mL (e.g., 700 ng/mL at 70 years). A negative D-dimer rules out PE with a 3-month failure rate <0.5%.
•If D-dimer is positive or pre-test probability is high, proceed to (CTPA), the gold standard. CTPA identifies PE in ~20% of suspected patients, and a negative CTPA rules out PE with a 3-month VTE risk of 0.0% (level 1 evidence).
•Use as an alternative when CTPA is contraindicated (severe contrast allergy, renal impairment, pregnancy) or in young women to reduce breast radiation. Planar V/Q has a negative predictive value >99% when interpreted as normal or low probability.
•In pregnancy, apply the pregnancy-adapted : evaluate three clinical criteria (clinical signs of DVT, hemoptysis, PE as most likely diagnosis). If 0 criteria, use D-dimer threshold of 1000 ng/mL; if ≥1 criteria, use 500 ng/mL. This approach avoided CTPA in 39% of pregnant women (65% in the first trimester) with a 0.21% 3-month VTE failure rate.
•Perform point-of-care ultrasound as a supplementary tool: a normal anterior lung profile plus evidence of DVT on compression ultrasound has 99% specificity for PE, but sensitivity is low (81%). A negative ultrasound does not rule out PE.
•Once PE is confirmed, immediately stratify risk using the . Score 1 point each for age >80 years, cancer, chronic cardiopulmonary disease, heart rate ≥110 bpm, SBP <100 mmHg, and SpO₂ <90%. A score of 0 identifies low-risk patients with ~1% 30-day mortality.
•Order cardiac biomarkers: high-sensitivity troponin (elevated in ~50% of PE patients) and NT-proBNP or BNP. Elevated BNP increases the odds of a complicated in-hospital course 6.8-fold (95% CI 4.4-10) and 30-day mortality 7.6-fold (95% CI 3.4-17). Use age-adjusted hsTnT: ≥14 pg/mL for age <75 years, ≥45 pg/mL for age ≥75 years.
•Obtain echocardiography or CT to assess RV function. RV dilation on CT (RV/LV ratio >1.0) increases 30-day mortality 2.08-fold (95% CI 1.63-2.66) and PE-related death 7.35-fold (95% CI 3.59-15.09). Echocardiographic signs of RV dysfunction (e.g., TAPSE <16 mm, McConnell's sign) further refine risk.
•Use the to select low-risk patients for outpatient management. The 11-item checklist includes hemodynamic instability, need for oxygen, active bleeding, severe renal impairment, and other comorbidities. If all criteria are negative, direct discharge is safe (30-day adverse outcome rate 1.1% in a randomized trial).

Management

•Initiate anticoagulation immediately once PE is confirmed and no contraindications exist. For most patients, start a direct oral anticoagulant (DOAC) without a parenteral lead-in.
•First-line: 10 mg orally twice daily for 7 days, then 5 mg twice daily for at least 3 months. In the COBRRA trial, apixaban caused significantly less clinically relevant bleeding than rivaroxaban (3.3% vs 7.1%; RR 0.46; NNT=27).
•Alternative: 15 mg orally twice daily for 21 days, then 20 mg once daily. Acceptable for patients who prefer once-daily dosing, but bleeding risk is higher than with apixaban.
•Alternative: 60 mg once daily after 5 days of parenteral anticoagulation (LMWH or UFH). Reduce to 30 mg once daily if CrCl 15-50 mL/min or body weight ≤60 kg.
•For patients with cancer-associated VTE, apixaban and edoxaban are preferred over LMWH. Apixaban is noninferior to dalteparin (HR 0.63 for recurrence) with similar major bleeding (3.8% vs 4.0%). After 6 months of full-dose therapy, consider reduced-dose apixaban 2.5 mg twice daily for extended secondary prevention (noninferior to 5 mg twice daily with fewer bleeding events).
•For high-risk (massive) PE with sustained hypotension (SBP <90 mmHg for ≥15 min or requiring vasopressors), administer immediate systemic fibrinolysis: as a single weight-based IV bolus (30-50 mg). This reduces death or hemodynamic decompensation from 5.6% to 2.6% (NNT=34) but increases major bleeding from 1.2% to 6.3% (NNH=20).
•For intermediate-risk PE (normotensive with RV dysfunction and elevated troponin) who develop cardiorespiratory distress (SBP ≤110 mmHg, heart rate ≥100 bpm, respiratory rate >20), consider ultrasound-facilitated catheter-directed fibrinolysis (UF-CDT) with alteplase. This reduces the composite of PE-related death, decompensation, or recurrence from 10.3% to 4.0% (RR 0.39; NNT=16) without excess intracranial hemorrhage.
•Provide supplemental oxygen to maintain SpO₂ ≥90% (≥92% in chronic lung disease). Do not give routine oxygen to normoxemic intermediate-risk patients, it does not improve RV recovery and may mask clinical deterioration.
•For hypotension, administer cautious fluid resuscitation (250-500 mL crystalloid boluses). If shock persists, start norepinephrine. Avoid excessive fluids that worsen RV distension.
•Monitor for bleeding: check hemoglobin, platelet count, and renal function at baseline and periodically. Anticoagulate for at least 3 months. For unprovoked PE with high recurrence risk (age >65, residual pulmonary vascular obstruction ≥5%, antiphospholipid antibodies), extend anticoagulation indefinitely.
•In patients with antiphospholipid syndrome, use warfarin (INR 2-3) rather than DOACs due to higher recurrence rates with DOACs.
•Refer patients with persistent dyspnea or exercise limitation after PE for structured rehabilitation, an 8-week program improves incremental shuttle walk test by 53 m (95% CI 17.7-88.3) and quality of life.
•Screen for chronic thromboembolic pulmonary hypertension (CTEPH) in patients with persistent dyspnea 3-6 months after PE: perform echocardiography and V/Q scan. If CTEPH is confirmed, refer to a pulmonary hypertension center for consideration of pulmonary endarterectomy.
•What NOT to do: Do not use systemic fibrinolysis in all intermediate-risk patients, the bleeding risk (6.3% major bleeding, 2.4% stroke) outweighs the benefit. Do not place inferior vena cava filters routinely, they increase DVT risk without improving survival. Do not discharge a patient with intermediate-risk PE to home without a plan for close follow-up.

Board Review — High Yield

•Single-question rule-out, Asking 'Is PE the most likely diagnosis?' simplifies pre-test probability and allows a D-dimer threshold of 1000 ng/mL when the answer is 'no', reducing chest imaging by 18%.
•Apixaban vs rivaroxaban bleeding, COBRRA trial: apixaban causes 46% less clinically relevant bleeding than rivaroxaban (3.3% vs 7.1%; NNT=27), making apixaban the preferred DOAC for acute VTE.
•CTEPH incidence, Pooled incidence of CTEPH after acute PE is 0.56% in all-comers but rises to 3.2% in survivors; unprovoked PE (OR 4.1) and recurrent VTE (OR 3.2) are strong predictors.
•Hestia criteria for outpatient management, A randomized trial showed that patients negative for all 11 Hestia criteria can be discharged directly with a 30-day adverse event rate of only 1.1%.
•Age-adjusted troponin cut-off, In patients ≥75 years, use hsTnT ≥45 pg/mL (not 14 pg/mL) for risk stratification; this improves the C-index to 0.77 and identifies 16.6% as higher risk.
•Pregnancy-adapted YEARS algorithm, Using 0 criteria + D-dimer <1000 ng/mL avoids CTPA in 39% of pregnant women (65% in first trimester) with a 0.21% 3-month VTE failure rate.
•Thrombolysis in intermediate-risk PE, PEITHO trial: tenecteplase reduces death or decompensation from 5.6% to 2.6% (NNT=34) but increases major bleeding from 1.2% to 6.3% (NNH=20) and stroke from 0.2% to 2.4%, reserved for deterioration.
•Reduced-dose apixaban for cancer, After 6 months of full-dose anticoagulation, apixaban 2.5 mg BID is noninferior to 5 mg BID for preventing recurrent VTE (2.1% vs 2.8%) and reduces clinically relevant bleeding (12.1% vs 15.6%; NNT=28).
•RV dilation on CT, RV/LV ratio >1.0 on CT is the strongest predictor of PE-related death (OR 7.35), outperforming clinical scores alone.
•Post-PE rehabilitation, An 8-week exercise program improves incremental shuttle walk test by 53 m and quality of life in patients with persistent dyspnea after PE.

Deep Dive — Evidence Details

1. Definition, Classification and Nomenclature

▸PE classification based on hemodynamics and RV function
▸CTEPH is a late complication in ~4% of survivors

HY High Yield: High-risk PE: SBP <90 mmHg for ≥15 min - immediate reperfusion needed.

Pulmonary embolism (PE) is obstruction of pulmonary arteries by thrombus, usually from lower extremity DVT. Synonyms: pulmonary thromboembolism, VTE (with DVT). High-risk (massive) PE: sustained hypotension (SBP <90 mmHg ≥15 min) ^[11]^B2b. Intermediate-risk (submassive): normotensive with RV dysfunction on echo or elevated biomarkers (troponin, NT-proBNP) ^[11]^B2b^[14]^B2a. Low-risk: no RV dysfunction, normal biomarkers. CTEPH is chronic sequelae with pulmonary hypertension >25 mmHg at rest >6 months after PE ^[13]^D5.

Category	Key Feature	Defining Criteria	Supporting Evidence
High-risk	Hemodynamic instability	Sustained hypotension or shock	^[11]^B2b
Intermediate-high	RV dysfunction + elevated biomarkers	Both present	^[11]^B2b
Intermediate-low	Either RV dysfunction or elevated biomarkers	One present	^[11]^B2b
Low-risk	No RV dysfunction, normal biomarkers	None of the above	^[11]^B2b
CTEPH	Chronic pulmonary hypertension	PA pressure >25 mmHg >6 months after PE	^[13]^D5

Pearl: The single most critical decision in acute PE is the initial hemodynamic assessment: a patient with sustained hypotension (systolic BP <90 mmHg) is high-risk and warrants immediate reperfusion, while every normotensive patient requires systematic risk stratification using RV imaging and cardiac biomarkers to guide the intensity of management.

3. Epidemiology, Etiology and Risk Factors

▸RV dysfunction and BNP are strongest predictors of mortality
▸CTEPH risk higher in unprovoked PE

HY High Yield: RV dilation on CT: OR 7.35 for PE-related death.

PE incidence in all-comers: CTEPH in 0.56% (95% CI 0.1-1.0%), rising to 3.2% in survivors ^[47]^A1a. 30-day adverse outcomes: 7.4% in normotensive derivation cohort, 4.5% validation ^[44]^B2b. Intermediate-risk: 10.3% with anticoagulation alone vs 4.0% with catheter-directed fibrinolysis ^[52]^A1b. Cancer-associated PE outpatient mortality 1.74% ^[39]^A1a.

Risk Factor	Odds Ratio (95% CI)	Evidence Level	Source
Elevated BNP/NT-proBNP for complicated in-hospital course	OR 6.8 (4.4-10)	High	^[42]^A1a
Elevated BNP/NT-proBNP for 30-day mortality	OR 7.6 (3.4-17)	High	^[42]^A1a
RV dilation on CT for 30-day mortality	OR 2.08 (1.63-2.66)	High	^[46]^A1a
RV dilation on CT for PE-related death	OR 7.35 (3.59-15.09)	High	^[46]^A1a
Unprovoked PE for CTEPH	OR 4.1 (2.1-8.2)	Moderate	^[47]^A1a
Recurrent VTE for CTEPH	OR 3.2 (1.7-5.9)	Moderate	^[47]^A1a

Pearl: The risk of PE-related death is most strongly predicted by right ventricular dysfunction (OR 7.35) and elevated BNP (OR 7.6), these biomarkers are essential for refining risk stratification beyond clinical factors alone.

4. Clinical Presentation

▸Dyspnea is most common symptom
▸Syncope suggests large central embolus

! Warning: SBP <90 mmHg or HR ≥110 bpm with RV strain = high risk.

Symptoms: dyspnea (most common), pleuritic chest pain, cough, hemoptysis, syncope. Signs: tachypnea, tachycardia (HR ≥110 bpm → aOR 1.87 for adverse outcomes ^[58]^B2b), hypotension (SBP 90-100 mmHg → aOR 2.45 ^[58]^B2b), hypoxia (SpO₂ <90% → increased 30-day mortality in cancer ^[61]^B2b), RV strain (elevated JVP, loud P2, tricuspid regurgitation). Red flags: SBP <90 mmHg, HR ≥110 bpm with RV strain, syncope, oxygen saturation <90%. Atypical: COPD exacerbation (24.7% PE prevalence ^[64]^B2a), cancer patients (asymptomatic UPE 30-day mortality 3% vs 20-21% symptomatic ^[61]^B2b).

Pearl: A normotensive patient with PE and heart rate ≥110 bpm, SBP 90-100 mmHg, or oxygen saturation <90% is at intermediate risk and warrants urgent risk stratification ^[58]^B2b^[61]^B2b.

Clinical Signs Associated with Adverse Outcomes in Acute PE

Sign	Adjusted Odds Ratio (95% CI)	Source
Systolic blood pressure 90-100 mmHg	2.45 (1.50-3.99)	Bova et al. ^[58]^B2b
Heart rate ≥110 beats/min	1.87 (1.31-2.69)	Bova et al. ^[58]^B2b
Elevated cardiac troponin	2.49 (1.71-3.69)	Bova et al. ^[58]^B2b
Right ventricular dysfunction (echocardiography)	2.28 (1.58-3.29)	Bova et al. ^[58]^B2b

6. Severity, Staging and Risk Stratification

▸High-risk PE is characterised in the cited evidence by shock, **systolic blood pressure <90 mmHg**, and/or ESC high-risk criteria. [176]
▸Intermediate-high-risk PE is defined in the cited treatment studies as a distinct group in which RV consequences, including the RV/LV ratio, are clinically important. [161][162]
▸CTPA pulmonary vascular obstruction scores, including the Qanadli index and simplified measures, may inform recurrence-risk research but should not be used as a standalone threshold for extended anticoagulation. [163]
▸Cancer-associated and incidental PE require structured assessment of haemodynamics, RV effects, bleeding risk and underlying malignancy; incidental detection is not synonymous with low risk. [176]
▸Acute severity and post-treatment recurrence risk are separate decisions requiring different assessment frameworks. [163][167]

! Warning: Do not equate a large CTPA obstruction score, incidental detection, frailty or cancer status with a single predefined acute-risk category. The cited evidence supports integrating these factors with haemodynamics and RV assessment rather than using any one feature in isolation. [163][170][176]

Scope and principles

Severity assessment in acute (PE) should combine haemodynamic status, right-ventricular (RV) consequences, pulmonary vascular obstruction, comorbidity and bleeding risk rather than relying on clot burden alone. Contemporary studies continue to distinguish high-risk PE, defined in the cited cohort using European Society of Cardiology (ESC) criteria, from intermediate-risk presentations; high-risk disease is linked to shock and/or marked hypotension. ^[176] Evidence available for this update is heterogeneous, including randomised trials, systematic reviews, retrospective cohorts and methodological studies, and therefore does not establish a single universally superior prognostic model. ^[161]^[162]^[169]

Haemodynamic staging

The most clinically consequential category is high-risk PE with haemodynamic compromise. In a contemporary cancer-associated PE cohort, a severe haemodynamic presentation composite endpoint was defined as shock, systolic blood pressure <90 mmHg, and/or high-risk PE according to ESC criteria. ^[176] This threshold is therefore a practical marker for urgent escalation and specialist assessment, although the composite definition should not be interpreted as proving that every patient with an isolated blood pressure below this value has identical mortality risk. ^[176]

Patients without overt shock may still have intermediate-risk disease. The BETULA randomised trial specifically enrolled patients with acute intermediate-high-risk PE, while comparative evidence on catheter-directed thrombolysis (CDT) includes both intermediate- and high-risk PE. ^[161]^[162] Intermediate-high-risk classification in these studies was clinically relevant because RV strain, rather than hypotension alone, was used to identify patients who might benefit from reperfusion strategies; the BETULA trial evaluated change in the RV/left-ventricular (RV/LV) ratio as a principal marker of treatment effect. ^[162]

RV dysfunction and imaging burden

RV dysfunction is an important severity discriminator in normotensive PE, but echocardiographic prognostic evidence should be interpreted cautiously. A methodological comparison study identified 63 prognostic cohort studies evaluating echocardiography in acute PE and compared four structured risk-of-bias tools, underscoring substantial methodological considerations when applying published echocardiographic associations to individual patients. ^[169]

Computed tomography pulmonary angiography (CTPA) can quantify pulmonary vascular obstruction using the Qanadli index. In the PADIS-PE post hoc analysis, initial obstruction was assessed in 180 patients with first unprovoked PE diagnosed by CTPA, using the Qanadli score, modified Qanadli score and simplified semiquantitative measures. ^[163] The study addressed recurrence after anticoagulation discontinuation, indicating that the initial pulmonary vascular obstruction phenotype may contribute to longer-term risk stratification; however, the available evidence does not justify using a single obstruction threshold as a standalone indication for prolonged anticoagulation. ^[163]

Cancer-associated and incidental PE

Active cancer may alter both presentation and management. In a real-world cohort of 381 hospitalised patients with acute PE, 58 had active cancer and 323 did not; the study compared cancer-associated PE with non-cancer PE using the severe haemodynamic presentation composite endpoint, clinical severity markers, management and in-hospital outcomes. ^[176] Routine oncological imaging has increased detection of incidental PE, potentially changing the observed clinical spectrum of cancer-associated PE. ^[176] Incidental detection should therefore prompt the same structured assessment of haemodynamics, RV effects, clot distribution, cancer status and bleeding risk as symptomatic PE, while the cited cohort does not establish that incidental PE is uniformly low risk. ^[176]

Treatment-response information in intermediate/high-risk disease

CDT is being evaluated as a reperfusion option for intermediate- and high-risk PE, with systematic-review evidence comparing it with anticoagulation alone. ^[161] The BETULA trial tested a low-dose, short-duration CDT strategy against unfractionated heparin in acute intermediate-high-risk PE and was designed around RV/LV-ratio improvement and safety. ^[162] These studies inform treatment selection after risk staging but do not support routine reperfusion for every intermediate-risk patient; the abstracts supplied here do not provide sufficient outcome estimates to define a universal treatment threshold. ^[161]^[162]

Modifiers of prognosis and recurrence

Frailty is an emerging modifier of venous-disease outcomes. A systematic review and meta-analysis evaluated associations between clinical frailty and venous diseases, including non-postoperative VTE and PE, but the available abstract does not provide pooled effect estimates; frailty should therefore be incorporated as a contextual prognostic factor rather than a validated acute PE staging category. ^[170]

Recurrence risk after treatment is distinct from acute haemodynamic severity. The PADIS-PE analysis examined recurrence after anticoagulation discontinuation in first unprovoked PE, whereas a prospective cohort evaluated recurrence after at least 3 months of anticoagulation in VTE provoked by transient risk factors classified according to International Society on Thrombosis and Haemostasis definitions. ^[163]^[167]^C These studies support separating acute-risk classification from decisions about treatment duration, because an initially stable patient may still require individualized assessment of recurrence risk after anticoagulation is stopped. ^[163]^[167]^C

Operational risk stratification

Artificial-intelligence-assisted CTPA detection and pulmonary embolism response-team workflows have been studied as methods to shorten time to diagnosis, anticoagulation and intervention, but the cited retrospective evidence addresses care processes rather than validating a new severity score. ^[177]^C Risk stratification should consequently remain anchored to haemodynamics, RV impact, imaging findings, cancer and frailty, with multidisciplinary review when deterioration or intermediate-high-risk features are present. ^[169]^[176]^[177]^C

Practical severity domains

Domain	Evidence-supported assessment	Clinical interpretation
Haemodynamics	Shock, or SBP <90 mmHg, and ESC high-risk PE criteria ^[176]	Supports high-risk classification and urgent escalation
RV impact	RV/LV ratio and echocardiographic findings ^[162]^[169]	Helps identify intermediate-high-risk disease, but prognostic evidence has methodological limitations ^[169]
Pulmonary obstruction	Qanadli, modified Qanadli and simplified CTPA measures ^[163]	May contribute to recurrence-risk assessment; no standalone treatment threshold is established ^[163]
Clinical modifiers	Active cancer, incidental detection and frailty ^[170]^[176]	Modify context and prognosis but do not independently replace acute haemodynamic staging ^[170]^[176]
Care pathway	PE response-team and AI-supported CTPA workflows ^[177]^C	May accelerate diagnosis and treatment; not a validated severity score ^[177]^C

7. Acute Management and Exacerbation Rescue

▸Treat abrupt cardiovascular collapse as a time-critical PE emergency and activate bedside diagnostics and multidisciplinary rescue. [190][193]
▸The cited intermediate-high-risk catheter studies used systolic blood pressure **≥90 mm Hg** and RV/LV ratio **≥0.9** as key enrollment thresholds. [162][196]
▸BETULA evaluates low-dose, short-duration CDT containing **4 mg r-tPA** per treated catheter segment versus UFH. [162]
▸A prospective multicenter study evaluated conical mesh-disc mechanical thrombectomy with a primary RV/LV endpoint at **48 hours**. [196]
▸Structured outpatient VTE pathways may include **1-week** specialist follow-up, a **30-day** DOAC prescription, and pharmacist-led education for selected low-risk patients. [194]
▸PERC, YEARS, and staged D-dimer reassessment are diagnostic strategies and must not delay treatment in unstable or highly suspicious presentations. [183][186][195]

! Warning: Device-specific, single-arm thrombectomy evidence and selected intermediate-high-risk CDT trials do not establish one universal reperfusion strategy for every patient with PE. Match rescue therapy to hemodynamics, RV burden, bleeding risk, local expertise, and multidisciplinary assessment. [162][196]

CP Clinical Pearl: A discharge pathway is an organized system, not simply a prescription: the cited model combined a **30-day** DOAC supply, pharmacist education, and **1-week** specialist follow-up. [194]

Dx Diagnostic Essentials: PERC, YEARS, and D-dimer reassessment are intended for diagnostic selection and imaging stewardship; they are not substitutes for urgent stabilization or definitive evaluation when the patient is unstable. [183][186][195]

Immediate recognition and stabilization

Acute pulmonary embolism (PE) may present to emergency medical services (EMS) and hospital teams with substantial short-term mortality, making early recognition, risk assessment, and coordinated escalation essential. In a population-based Australian cohort of EMS-treated PE, prehospital records were linked with hospital and death registries to characterize presentation and 30-day all-cause mortality, providing real-world outcome data for emergency systems. ^[190] Peri-induction PE can cause abrupt cardiovascular collapse; a reported case emphasizes immediate bedside diagnostic assessment and multidisciplinary rescue during anesthesia induction. ^[193]

Patients with suspected or confirmed PE should be managed according to initial hemodynamic status and right-ventricular (RV) burden. The contemporary interventional studies summarized here enrolled patients with intermediate-high-risk PE who were normotensive, with systolic blood pressure ≥90 mm Hg, and evidence of RV strain defined by an RV/LV diameter ratio ≥0.9. ^[162]^[196] These eligibility criteria should not be extrapolated to patients with shock or persistent hypotension, who require urgent specialist evaluation for advanced reperfusion or mechanical circulatory support. ^[162]^[196]

Reperfusion rescue and catheter-based treatment

Catheter-directed thrombolysis (CDT) is being evaluated as a lower-dose alternative to earlier ultrasound-assisted protocols that used larger thrombolytic doses and prolonged infusions. The BETULA randomized trial compared low-dose, short-duration CDT with unfractionated heparin (UFH) in acute intermediate-high-risk PE and used a regimen containing 4 mg recombinant tissue plasminogen activator (r-tPA) per treated catheter segment as specified in the trial protocol. ^[162] The study was designed to assess both RV/LV-ratio improvement and safety, addressing concerns that higher thrombolytic exposure, longer infusion duration, cost, and complications may limit broader CDT use. ^[162]

Mechanical thrombectomy is another catheter-based rescue or decongestion strategy. A prospective, multicenter, single-arm study evaluated a conical nitinol mesh-disc system in adults with CTPA-confirmed acute PE, symptom duration ≤14 days, systolic blood pressure ≥90 mm Hg, and baseline RV/LV ratio ≥0.9. ^[196] Its primary effectiveness endpoint was the change in CTPA-derived RV/LV ratio at 48 hours, while the primary safety endpoint was major adverse events during follow-up. ^[196] Because this evidence is single-arm and device-specific, it supports feasibility and safety assessment rather than universal substitution for anticoagulation, systemic thrombolysis, surgery, or established catheter techniques. ^[196]

A perioperative collapse case illustrates that rescue treatment must be individualized to the clinical context, with real-time bedside diagnostics, rapid hemodynamic support, and multidisciplinary coordination used during catastrophic PE under anesthesia. ^[193]

Anticoagulation and disposition of low-risk patients

The reviewed discharge-pathway study supports structured outpatient management for carefully selected low-risk patients with VTE. The pathway incorporated a 1-week outpatient vascular-medicine follow-up appointment, a 30-day direct oral anticoagulant (DOAC) prescription, and anticoagulant education delivered by an emergency-department pharmacist. ^[194] This evidence concerns implementation and real-world practice rather than a universal discharge rule; outpatient treatment should therefore depend on validated low-risk assessment, clinical stability, reliable medication access, and follow-up capability. ^[194]

Diagnostic safeguards during acute evaluation

Diagnostic stewardship can reduce unnecessary imaging, but the cited evidence applies to suspected PE rather than treatment of confirmed disease. A systematic review and meta-analysis evaluated the eight-item Pulmonary Embolism Rule-out Criteria (PERC) in very-low-risk emergency-department patients and examined its effect on CTPA utilization. ^[186] In patients with active cancer, the randomized Hydra trial compared the YEARS algorithm with a CTPA-only strategy and directly addressed whether algorithm-guided exclusion could safely reduce imaging in this higher-complexity population. ^[183] A separate exploratory cohort reassessed patients referred with elevated community D-dimer using a three-step strategy: clinical probability reassessment, adjustment of community D-dimer thresholds, and repeat ED D-dimer testing with the VIDAS assay. ^[195]^C These approaches should not delay treatment or definitive imaging when clinical instability or high suspicion is present. ^[183]^[186]^[195]^C

Follow-up after the acute episode

Persistent or recurrent dyspnea after PE warrants assessment for chronic pulmonary vascular disease. A six-month cohort investigated TAC1 promoter methylation and expression in relation to transition from acute PE to chronic thromboembolic pulmonary hypertension (CTEPH), reflecting ongoing research into biological predictors of this complication. ^[188] For established CTEPH treated with pulmonary endarterectomy, a systematic review examined the safety and feasibility of early postoperative exercise while considering cardiac remodeling and recovery. ^[180] These findings concern post-acute rehabilitation and surveillance, not immediate rescue of unstable PE. Sex-specific long-term outcomes, including mortality, pulmonary hypertension, CTEPH, and chronic respiratory sequelae, have also been examined in a large propensity-matched cohort with a 90-day landmark analysis. ^[192]

Evidence-informed acute PE pathways from the cited literature

Clinical situation	Evidence-supported action or consideration	Reference
EMS or emergency presentation	Rapid recognition, linkage to emergency and hospital systems, and attention to 30-day outcomes	^[190]
Peri-induction cardiovascular collapse	Immediate bedside assessment and multidisciplinary rescue	^[193]
Intermediate-high-risk, normotensive PE	Consider specialist evaluation for CDT or mechanical thrombectomy within studied eligibility parameters	^[162]^[196]
Selected low-risk VTE	Structured discharge pathway with DOAC supply, pharmacist education, and early follow-up	^[194]
Active cancer with suspected PE	YEARS-based diagnostic evaluation is being tested against CTPA-only assessment	^[183]
Very-low-risk suspected PE	PERC may reduce imaging when applied to appropriately selected patients	^[186]

8. Long-term and Definitive Management

▸The supplied references do not establish a universal duration of anticoagulation after acute PE; treatment duration must be individualized. [107][199]
▸After anticoagulation cessation in the RIDTS distal-DVT cohort, recurrent VTE occurred in 15.3% of participants, with a median time to recurrence of 6.2 months. [199]
▸Long-term edoxaban has been evaluated in a prospective real-world CTEPH registry, but the supplied abstract does not provide numerical outcomes or comparative superiority data. [107]
▸Post-PE echocardiographic follow-up is particularly relevant for survivors treated with CDT, CDE, or SPE, although available evidence is retrospective and survivor-limited. [206]
▸BETULA randomized low-dose, short-duration CDT against UFH in intermediate-high-risk PE, but the supplied abstract excerpt does not report efficacy or safety results. [162]

CP Clinical Pearl: A recurrence occurring after anticoagulation cessation should trigger reassessment of the original provoking context, bleeding risk, and whether an unrecognized chronic thromboembolic disorder or persistent risk factor is present. [107][199]

! Warning: Do not extrapolate the 6-versus-12-week RIDTS findings in isolated distal DVT directly to anticoagulation duration after pulmonary embolism. [199]

Scope of the available evidence

The supplied evidence addresses three distinct phases of pulmonary embolism (PE) care: acute escalation for intermediate-high-risk PE, outpatient assessment of right-ventricular (RV) recovery, and long-term treatment of chronic thromboembolic pulmonary hypertension (CTEPH). It does not provide a complete evidence base for selecting initial anticoagulant, routine duration of anticoagulation after all forms of PE, inferior vena cava-filter use, or standardized post-PE clinic protocols. ^[162]^[107]^B2b^[206]

Anticoagulation and duration decisions

Duration should be individualized according to recurrence risk, bleeding risk, provoking factors, residual thrombotic disease, and the presence of chronic thromboembolic complications; however, the supplied references do not establish a universal duration for anticoagulation after acute PE. Evidence from the randomized RIDTS population—patients with isolated distal deep-vein thrombosis (IDDVT) without cancer—shows that extending rivaroxaban from 6 to 12 weeks did not eliminate later recurrence: 61 of 398 participants (15.3%) developed recurrent VTE after treatment cessation, with a median interval of 6.2 months. ^[199]

Among these recurrences, 77% were recurrent IDDVT, 23% were proximal DVT or symptomatic PE, and symptomatic PE accounted for five events (8.2% of the total cohort); 63.9% of recurrences were symptomatic and 36.1% asymptomatic. ^[199] These findings concern distal DVT rather than established PE and should not be directly extrapolated to determine PE-treatment duration, but they support continued reassessment after anticoagulation is stopped, particularly when recurrence risk is uncertain. ^[199]

Long-term VTE risk may also be influenced by persistent conditions. In a Danish nationwide cohort, women with endometriosis were evaluated for long-term VTE risk, with VTE defined as DVT or PE; the supplied abstract confirms the study population and outcome framework but does not provide the effect estimate in the available text. ^[207] Similarly, a propensity-matched analysis of hypertensive disorders of pregnancy evaluated PE among five-year cardiovascular outcomes, but the supplied abstract does not report the PE-specific numerical results. ^[178]

CTEPH: definitive evaluation and long-term treatment

Patients with persistent dyspnoea, exercise limitation, or RV abnormalities after acute PE require assessment for chronic thromboembolic disease; the provided references specifically address patients already diagnosed with CTEPH. ^[107]^B2b In a prospective nationwide registry, long-term edoxaban effectiveness and safety were evaluated in patients with CTEPH. The composite morbidity/mortality endpoint included all-cause death, lung transplantation, rescue pulmonary endarterectomy or balloon pulmonary angioplasty, a ≥15% decline in 6-minute-walk distance with worsening World Health Organization functional class, or symptomatic deterioration. ^[107]^B2b

The available abstract does not provide the registry’s numerical event rates, comparative estimates, or subgroup findings. Therefore, it supports edoxaban as an actively studied real-world long-term anticoagulant strategy in CTEPH, but does not establish its superiority over other anticoagulants or define when anticoagulation can safely be discontinued. ^[107]^B2b

Follow-up after advanced acute-PE therapy

Outpatient echocardiographic follow-up is clinically relevant in survivors treated for intermediate- to high-risk PE. A retrospective PERT-managed study compared survivors who received catheter-directed thrombolysis (CDT), catheter-directed embolectomy (CDE), or surgical pulmonary embolectomy (SPE), using baseline and follow-up echocardiography and propensity-score matching based on six variables, including age, body-mass index, and PESI score. ^[206] The study was designed to examine associations between advanced therapy and later RV function; because it was retrospective and restricted to survivors with follow-up echocardiography, its results should be interpreted as observational associations rather than proof that advanced therapy improves long-term outcomes. ^[206]

When definitive reperfusion is considered

For acute intermediate-high-risk PE, the BETULA open-label randomized trial compared low-dose, short-duration CDT with unfractionated heparin. The CDT regimen used 4 mg recombinant tissue plasminogen activator per treatment arm in the supplied abstract, and the trial was designed to test whether a shorter, lower-dose approach could reduce RV/LV ratio while limiting the costs and complications associated with ultrasound-assisted devices, higher thrombolytic doses, and prolonged infusions. ^[162] The supplied abstract excerpt does not report the trial’s efficacy, bleeding, mortality, or functional-outcome results; consequently, it cannot by itself establish CDT as routine definitive therapy. ^[162]

Practical long-term pathway

After acute PE, document the provoking context, bleeding considerations, anticoagulant plan, and intended reassessment point, while educating patients about recurrent PE symptoms and bleeding. Persistent or worsening exercise limitation should prompt structured clinical and cardiopulmonary reassessment, with echocardiography particularly relevant when RV dysfunction was present or advanced therapy was used. ^[206] Confirmed CTEPH requires specialist evaluation because the long-term disease framework includes anticoagulation and possible pulmonary endarterectomy, balloon pulmonary angioplasty, rescue intervention, or transplantation as outcome-relevant pathways. ^[107]^B2b Decisions about CDT, embolectomy, or surgery should be individualized by a multidisciplinary PE team, since the available evidence includes an acute randomized CDT trial whose reported results are incomplete here and a retrospective follow-up study subject to survivor and selection bias. ^[162]^[206]

Evidence-informed long-term management framework

Clinical situation	Evidence-supported consideration	Important limitation
Anticoagulation after acute PE	Individualize duration; reassess recurrence and bleeding risk. ^[199]	No universal PE duration is established by the supplied references. ^[107]^B2b^[199]
Post-treatment recurrence surveillance	Recurrence can occur months after anticoagulation cessation; the RIDTS cohort reported 15.3% recurrent VTE. ^[199]	RIDTS studied isolated distal DVT, not established PE. ^[199]
Persistent symptoms or RV abnormality	Arrange outpatient clinical and echocardiographic reassessment. ^[206]	Follow-up evidence is retrospective and limited to survivors with paired echocardiograms. ^[206]
Confirmed CTEPH	Long-term anticoagulation and specialist assessment for endarterectomy, balloon angioplasty, rescue intervention, or transplantation pathways. ^[107]^B2b	The supplied registry abstract does not provide event rates or treatment comparisons. ^[107]^B2b
Intermediate-high-risk acute PE	CDT is being evaluated as a lower-dose, shorter-duration reperfusion strategy. ^[162]	BETULA results are not reported in the supplied abstract excerpt. ^[162]

9. Respiratory Support, Procedures & Interventional Pulmonology

▸Mechanical thrombectomy effective in massive PE
▸Pulmonary endarterectomy for CTEPH

HY High Yield: Post-PVR <590 dynes·s·cm⁻⁵ predicts better survival after PEA.

In massive PE, mechanical thrombectomy can be life-saving, even in lung transplant recipients ^[118]^C4. Bronchoscopic cryoextraction restores airway patency from thrombi ^[110]^C4. Bronchial artery embolization for hemoptysis ^[111]^D5. ECMO with concurrent procedures: hemorrhagic complications in 26% ^[105]^B2a. IVC filters: retrieval rate 66.3% in lung transplant recipients ^[112]^C4. Donor lungs with PE can be salvaged with backtable thromboendarterectomy ^[117]^C4. Pulmonary endarterectomy for CTEPH: immediate postoperative PVR <590 dynes·s·cm⁻⁵ predicts better survival ^[104]^B2b.

Procedure	Indication	Key Evidence	Clinical Outcome
Mechanical thrombectomy	Acute massive PE in lung transplant recipients	^[118]^C4	Immediate hemodynamic improvement
Cryoextraction	Airway obstruction from PE thrombi	^[110]^C4	Partial/complete patency restoration
Bronchial artery embolization	Hemoptysis from PE	^[111]^D5	Effective hemostasis
Pulmonary endarterectomy	CTEPH	^[104]^B2b	PVR normalization if PVR <590 dynes·s·cm⁻⁵
IVC filter placement	VTE in lung transplant recipients	^[112]^C4	Retrieval rate 66.3%

Pearl: In lung transplant recipients, a high index of suspicion for PE is warranted given the 8.6% incidence and associated hypercoagulable abnormalities; mechanical thrombectomy and IVC filters can be safely employed in this population, and donor lungs with PE can be used after backtable thromboendarterectomy.

10. Complications

▸Acute PE may cause right-ventricular failure, obstructive shock, cardiac arrest, and death; the supplied evidence does not provide a universal complication rate [162].
▸CTEPH is a serious late complication of PE; pulmonary endarterectomy is the gold-standard treatment for operable disease [180].
▸Postoperative VTE and PE are important complications in orthopaedic, oncologic, reconstructive, and arthroplasty populations [174,209,210,213,214].
▸Anticoagulation, thrombolysis, and invasive procedures introduce bleeding, access-site, vascular, and device-related risks [160,162,165,205,211].
▸Evidence from traumatic haemorrhage, ECMO, DVT thrombectomy, and unrelated surgical cohorts should not be presented as direct evidence for PE-specific complication rates [165,208,211].

! Warning: Do not extrapolate complication rates from traumatic haemorrhagic shock, ECMO, DVT thrombectomy, or unrelated postoperative cohorts to patients with acute PE [165,208,211].

HY High Yield: Persistent or recurrent dyspnoea after PE warrants consideration of chronic thromboembolic disease, including CTEPH; the supplied evidence supports specialist evaluation but does not define a universal screening threshold [180,188].

Pulmonary embolism (PE) can cause acute cardiopulmonary deterioration, recurrent venous thromboembolism (VTE), bleeding related to treatment, and persistent pulmonary vascular disease. The supplied evidence base is heterogeneous: it includes studies of PE itself, chronic thromboembolic disease, perioperative VTE, anticoagulation, catheter complications, and thrombus-treatment devices, but it does not provide a single contemporary estimate for the overall complication rate after PE.

Acute cardiopulmonary complications

The immediate danger of PE is right-ventricular pressure overload, which may progress to right-ventricular failure, systemic hypotension, obstructive shock, cardiac arrest, and death. In patients classified as intermediate-high risk, catheter-directed thrombolysis (CDT) has been investigated as a strategy to reduce right-ventricular strain; the BETULA trial specifically compared low-dose, short-duration recombinant tissue plasminogen activator with unfractionated heparin because earlier ultrasound-assisted, higher-dose and longer-infusion approaches could increase complications and costs ^[162]. The abstract supplied for BETULA does not report the trial’s numerical bleeding, mortality, or recurrent-PE outcomes; these should therefore not be inferred from the available evidence ^[162].

Recurrent VTE and thromboembolic complications

Recurrent DVT or PE remains a clinically important complication in patients with VTE, particularly when risk factors persist or anticoagulation is interrupted. The 2026 Austrian interdisciplinary consensus identifies VTE—including DVT and PE—as a frequent and potentially life-threatening complication in orthopaedic and traumatology patients and updates prevention strategies for musculoskeletal procedures ^[209]. In elderly patients undergoing hip replacement after femoral-neck fracture, DVT is sufficiently consequential that a validated prediction nomogram was developed to identify postoperative risk and reduce progression to severe complications such as PE ^[210].

Postoperative PE has also been documented after major oncologic and reconstructive procedures. In patients undergoing oral squamous-cell-carcinoma resection with immediate radial forearm free-flap reconstruction, a multicentre retrospective cohort study evaluated PE during the index hospitalisation and assessed whether centre-specific perioperative management was associated with risk ^[213]. After cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal-origin pseudomyxoma peritonei, thromboembolic events were prospectively recorded, with routine postoperative day-10 duplex screening for DVT and CT pulmonary angiography for symptomatic suspected PE ^[214]. These studies support procedure-specific vigilance but do not establish a universal postoperative PE rate from the supplied abstracts ^[213]^[214].

VTE, including PE, is uncommon but potentially serious after total or reverse shoulder arthroplasty; a national database study assessed events occurring within 90 days and examined demographic, comorbidity, hospital-stay, and Charlson Comorbidity Index associations ^[174]^C. Frailty is also relevant: a systematic review and meta-analysis evaluated associations between clinical frailty, non-postoperative VTE, PE, and adverse venous-disease outcomes, although the supplied abstract does not report pooled effect estimates ^[170].

Chronic thromboembolic complications

Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious late complication of PE caused by persistent thromboembolic obstruction and pulmonary vascular disease, with high pulmonary arterial pressures ^[180]. Pulmonary endarterectomy is described as the gold-standard treatment for operable CTEPH and can improve outcomes; postoperative cardiac remodelling and the safety of early exercise are important considerations ^[180]. A six-month ambispective cohort investigated whether TAC1 promoter methylation was associated with transition from acute PE to CTEPH, representing exploratory evidence for a possible biological marker rather than a validated clinical predictor ^[188].

Treatment-related bleeding and vascular complications

Anticoagulation and thrombolysis may produce major bleeding, while invasive catheter procedures may cause access-site, vascular, or device-related complications. BETULA was designed partly to address the potential complication burden of higher thrombolytic doses and prolonged infusions ^[162]. Evidence concerning chronic antithrombotic therapy is indirect but clinically relevant when PE treatment intersects with surgery: a systematic review of total knee arthroplasty included 17 retrospective studies, with 104,182 patients receiving chronic antithrombotic therapy and 261,139 controls, and evaluated postoperative outcomes by antithrombotic class ^[205]. A separate study of intraoperative VA-ECMO during bilateral lung transplantation compared zero-, low-, and high-intensity heparin strategies, reflecting the balance between thrombosis and bleeding in highly invasive cardiopulmonary support ^[165]^C. Neither abstract establishes a PE-specific anticoagulant bleeding rate ^[165]^C^[205].

Catheter selection may influence complications during prolonged intravenous therapy, although the evidence is not PE-specific. A systematic review and meta-analysis of 15 studies—three randomised trials and 12 cohort studies—compared midline catheters with PICCs for complication rates ^[160]. These findings may inform venous-access decisions during PE care but should not be interpreted as evidence that either catheter prevents or causes PE ^[160].

Important evidence boundaries

Studies of prehospital whole-blood resuscitation address traumatic haemorrhagic shock rather than PE and therefore cannot be extrapolated to routine PE resuscitation ^[208]. Similarly, comparative mechanical-thrombectomy evidence for acute lower-extremity DVT concerns prevention of downstream PE and device-related haemolysis or embolic complications, not primary treatment of established PE ^[211]. Data on immediate weight-bearing after pelvic-ring fracture, perioperative antihypertensive exposure after shoulder arthroplasty, severe immune-checkpoint-inhibitor pneumonitis, and timing of non-cardiac surgery after myocardial infarction provide contextual information about competing postoperative risks but do not define complications of PE itself ^[172]^[175]^[179]^[189].

Complication domains supported by the supplied evidence

Domain	Evidence and clinical relevance
Acute haemodynamic compromise	Intermediate-high-risk PE studies evaluate right-ventricular strain and treatment-related complications ^[162].
Recurrent or postoperative VTE	Risk is examined in orthopaedic, arthroplasty, oncologic, and reconstructive settings ^[174]^C^[209]^[210]^[213]^[214].
CTEPH	Persistent thromboembolic disease may lead to high pulmonary arterial pressures; pulmonary endarterectomy is the established surgical treatment for operable disease ^[180].
Treatment-related complications	Thrombolysis and anticoagulation require balancing thrombosis against bleeding; catheter and thrombectomy devices may add procedural risks ^[160]^[162]^[165]^C^[205]^[211].

11. Prognosis and Natural History

▸Normotensive PE mortality ~2-4% with risk stratification
▸Bova stage III: 29.2% complication rate

HY High Yield: Catheter-directed fibrinolysis NNT 16 to prevent adverse outcome.

30-day mortality: low-risk ~1.9% ^[129]^A1a, unselected normotensive ~7.4% ^[83]^B2b, high-risk on ECMO 42.8% ^[49]^A1a. Intermediate-risk placebo group in PEITHO: 5.6% death/decompensation at 7 days ^[93]^A1b. Bova score stage III: 29.2% complication rate ^[58]^B2b. Treatment effect: apixaban vs rivaroxaban lower bleeding (RR 0.46, NNT 27) ^[92]^A1b; tenecteplase reduces decompensation (NNT 34) but increases major bleeding (NNH 20) ^[93]^A1b; catheter-directed fibrinolysis reduces composite (RR 0.39, NNT 16) ^[52]^A1b. Long-term: CTEPH in 3.2% survivors ^[47]^A1a; cancer patients on extended reduced-dose apixaban mortality ~17.7% at 12 months ^[50]^A1b.

Pearl: The 30-day mortality in normotensive PE is low (≈2-4%) with appropriate risk stratification, but intermediate-risk patients (Bova stage III) have a 29.2% complication rate, these patients may benefit from escalation of therapy beyond anticoagulation alone ^[58]^B2b.

Risk Stratification Scores for Normotensive Pulmonary Embolism

Score	Components	Risk Categories	30-Day Complication Rate
sPESI + BNP	Age >80, cancer, chronic cardiopulmonary disease, HR ≥110, SBP <100, O2 sat <90%; BNP >500 ng/L	Low vs high	NPV 99.1-100% for complicated course ^[44]^B2b
Bova	SBP 90-100 mmHg, HR ≥110, elevated troponin, RVD	Stage I (0-2), II (3-4), III (5-7)	4.2%, 10.8%, 29.2% ^[58]^B2b
Hestia	11 clinical criteria (hemodynamic instability, hypoxia, bleeding risk, etc.)	Low risk (none met)	1.1% (95% CI 0.2-3.2%) ^[40]^A1b

13. Prevention, Screening & Surveillance

▸Thromboprophylaxis for 10-35 days after orthopedic surgery
▸DOACs preferred over VKA for secondary prevention

HY High Yield: CHEST 2016: DOACs over VKA for non-cancer VTE (Grade 2B).

Primary prevention: thromboprophylaxis after major orthopedic surgery (LMWH, DOACs, aspirin, IPC) for 10-35 days (Grade 1B) ^[6]^A1c. No routine Doppler screening before discharge (Grade 1B) ^[6]^A1c. Statins may slightly reduce VTE (OR 0.86) but not PE ^[149]^A1a. Olanzapine increases VTE risk (OR 2.07) ^[156]^A1a. Secondary prevention: CHEST 2016 recommends DOACs over VKA for non-cancer VTE (Grade 2B) ^[4]^A1c. For cancer, LMWH or DOAC (Grade 2C) ^[4]^A1c. If recurrence on DOAC, switch to LMWH (Grade 2C) ^[4]^A1c. Subsegmental PE without proximal DVT: clinical surveillance if low risk (Grade 2C) ^[4]^A1c. IVC filters not recommended routinely (Grade 1B) ^[4]^A1c.

Pearl: The most impactful prevention strategy is appropriate thromboprophylaxis in hospitalized surgical and medical patients, guided by validated risk scores; the CHEST guidelines recommend against routine Doppler screening before discharge after orthopedic surgery, emphasizing that pharmacologic prophylaxis, not surveillance, is the cornerstone of prevention.

Summary of Primary Prevention Strategies for Pulmonary Embolism

Population	Recommended Prophylaxis	Duration	Grade	Source
Major orthopedic surgery	LMWH, fondaparinux, DOACs, LDUH, VKA, aspirin, or IPCD	Minimum 10-14 days, extend to 35 days	1B (pharmacologic), 1C (IPCD)	CHEST 2012 ^[6]^A1c
Hemodynamically unstable pelvic fractures	Early chemoprophylaxis (initiate hospital day 1)	Ongoing during hospitalization	,	Observational ^[159]^B2b
Degenerative spine surgery	Maintain thromboembolic vigilance for up to 4 months	Extended beyond typical perioperative window	,	Observational ^[157]^B2b
General medical patients with no prior VTE	Statins not recommended for primary PE prevention	,	Low-certainty evidence	Cochrane 2024 ^[149]^A1a
Patients on olanzapine	Enhanced clinical surveillance	,	,	Meta-analysis ^[156]^A1a

References

[1]
Leung AN, Bull TM, Jaeschke R et al.. “An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy.” American journal of respiratory and critical care medicine (2011). PMID: 22086989 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy
[2]
Lahm T, Douglas IS, Archer SL et al.. “Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.” American journal of respiratory and critical care medicine (2018). PMID: 30109950 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management, 10. Complications
[3]
Stevens SM, Woller SC, Kreuziger LB et al.. “Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.” Chest (2021). PMID: 34352278 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History
[4]
Kearon C, Akl EA, Ornelas J et al.. “Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.” Chest (2016). PMID: 26867832 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[5]
Kearon C, Akl EA, Comerota AJ et al.. “Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315268 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment
[6]
Falck-Ytter Y, Francis CW, Johanson NA et al.. “Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315265 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[7]
Stevens SM, Woller SC, Baumann Kreuziger L et al.. “Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.” Chest (2021). PMID: 34352279 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History
[8]
Linkins LA, Dans AL, Moores LK et al.. “Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315270 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 10. Complications
[9]
Moores LK, Tritschler T, Brosnahan S et al.. “Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report.” Chest (2020). PMID: 32502594 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
[10]
Eikelboom JW, Karthikeyan G, Fagel N et al.. “American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?” Chest (2009). PMID: 19201714 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature
[11]
Hellenkamp K, Pruszczyk P, Jiménez D et al.. “Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study.” The European respiratory journal (2018). PMID: 29599188 ↗
L2PROSPECTIVE_COHORTCited in: 1. Definition, Classification and Nomenclature
[12]
Piroth L, Cottenet J, Mariet AS et al.. “Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 33341155 ↗
L3RETROSPECTIVE_COHORTCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[13]
Viswanathan G, Kirshner HF, Nazo N et al.. “Single-Cell Analysis Reveals Distinct Immune and Smooth Muscle Cell Populations that Contribute to Chronic Thromboembolic Pulmonary Hypertension.” American journal of respiratory and critical care medicine (2023). PMID: 36803741 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism
[14]
Cimini LA, Candeloro M, Pływaczewska M et al.. “Prognostic role of different findings at echocardiography in acute pulmonary embolism: a critical review and meta-analysis.” ERJ open research (2023). PMID: 37009027 ↗
L2SR_COHORTCited in: 1. Definition, Classification and Nomenclature
[15]
O'Connor D, Johnston RV, Brignardello-Petersen R et al.. “Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears).” The Cochrane database of systematic reviews (2022). PMID: 35238404 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature
[16]
Lloyd TD, Geneen LJ, Bernhardt K et al.. “Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery.” The Cochrane database of systematic reviews (2023). PMID: 37681564 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy
[17]
Junqueira DR, Zorzela LM, Perini E. “Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.” The Cochrane database of systematic reviews (2017). PMID: 28431186 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature
[18]
Kim TY, Ahn GJ, Cha KC et al.. “2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 5. Cardiac arrest in special circumstances.” Clinical and experimental emergency medicine (2026). PMID: 42297408 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
[19]
Dorfman SR, Chan SS, Amanullah S et al.. “ACR Appropriateness Criteria® Chest Pain-Child.” Journal of the American College of Radiology : JACR (2026). PMID: 41729147 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature
[20]
Huie TJ, Olson AL, Cosgrove GP et al.. “A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes.” Respirology (Carlton, Vic.) (2010). PMID: 20546190 ↗
L4COHORTCited in: 1. Definition, Classification and Nomenclature
[21]
Le Pennec R, Le Roux PY, Robin P et al.. “Comparison of Three Diagnostic Strategies for Suspicion of Pulmonary Embolism: Planar Ventilation-Perfusion Scan (V/Q), Computed Tomography Pulmonary Angiography (CTPA), and Single Photon Emission Computed Tomography Ventilation-Perfusion Scan (SPECT V/Q): a multicenter, non-inferiority randomised controlled trial.” The European respiratory journal (2026). PMID: 41927066 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment
[22]
Tromeur C, Sanchez O, Presles E et al.. “Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.” The European respiratory journal (2018). PMID: 29301920 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[23]
Lee LA, Bailes Z, Barnes N et al.. “Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.” The Lancet. Respiratory medicine (2020). PMID: 32918892 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[24]
. “Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 41240959 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History
[25]
Harris B, Bailey D, Miles S et al.. “Objective analysis of tomographic ventilation-perfusion scintigraphy in pulmonary embolism.” American journal of respiratory and critical care medicine (2007). PMID: 17363770 ↗
L3PROSPECTIVE_COHORTCited in: 2. Pathophysiology and Mechanism
[26]
Scagliotti GV, Gaafar R, Nowak AK et al.. “Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.” The Lancet. Respiratory medicine (2019). PMID: 31103412 ↗
L1RCT_PHASE2Cited in: 2. Pathophysiology and Mechanism
[27]
Hemnes AR, Newman AL, Rosenbaum B et al.. “Bedside end-tidal CO2 tension as a screening tool to exclude pulmonary embolism.” The European respiratory journal (2009). PMID: 19717480 ↗
L2NON_RANDOMIZED_TRIALCited in: 2. Pathophysiology and Mechanism
[28]
Le Duc-Pennec A, Le Roux PY, Cornily JC et al.. “Diagnostic accuracy of single-photon emission tomography ventilation/perfusion lung scan in the diagnosis of pulmonary embolism.” Chest (2011). PMID: 21852295 ↗
L2PROSPECTIVE_COHORTCited in: 2. Pathophysiology and Mechanism
[29]
Salaun PY, Couturaud F, Le Duc-Pennec A et al.. “Noninvasive diagnosis of pulmonary embolism.” Chest (2010). PMID: 20724733 ↗
L2NON_RANDOMIZED_TRIALCited in: 2. Pathophysiology and Mechanism
[30]
van der Pol LM, Tromeur C, Bistervels IM et al.. “Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism.” The New England journal of medicine (2019). PMID: 30893534 ↗
L2NON_RANDOMIZED_TRIALCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy
[31]
Fernandes TM, Alotaibi M, Strozza DM et al.. “Dyspnea Postpulmonary Embolism From Physiological Dead Space Proportion and Stroke Volume Defects During Exercise.” Chest (2019). PMID: 31759962 ↗
L3COHORTCited in: 2. Pathophysiology and Mechanism
[32]
Miles S, Rogers KM, Thomas P et al.. “A comparison of single-photon emission CT lung scintigraphy and CT pulmonary angiography for the diagnosis of pulmonary embolism.” Chest (2009). PMID: 19525358 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism
[33]
Morris TA, Marsh JJ, Chiles PG et al.. “Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.” American journal of respiratory and critical care medicine (2006). PMID: 16514114 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism
[34]
Delcroix M, Torbicki A, Gopalan D et al.. “ERS statement on chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2021). PMID: 33334946 ↗
L1NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism
[35]
Jorens PG, Van Marck E, Snoeckx A et al.. “Nonthrombotic pulmonary embolism.” The European respiratory journal (2009). PMID: 19648522 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism
[36]
Kim NH, Delcroix M, Jais X et al.. “Chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2019). PMID: 30545969 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism
[37]
Agnelli G, Becattini C. “Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach.” The European respiratory journal (2015). PMID: 25700388 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism
[38]
Mercier O, Fadel E. “Chronic thromboembolic pulmonary hypertension: animal models.” The European respiratory journal (2013). PMID: 23314897 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism
[39]
Delluc A, Pradier M, Siegal DM et al.. “Outpatient management of cancer-associated pulmonary embolism: a systematic review and meta-analysis.” The European respiratory journal (2025). PMID: 39603673 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[40]
den Exter PL, Zondag W, Klok FA et al.. “Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2016). PMID: 27030891 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[41]
Fernando SM, Tran A, Cheng W et al.. “VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis.” Chest (2021). PMID: 34419428 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors
[42]
Klok FA, Mos IC, Huisman MV. “Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis.” American journal of respiratory and critical care medicine (2008). PMID: 18556626 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[43]
Lankeit M, Kempf T, Dellas C et al.. “Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism.” American journal of respiratory and critical care medicine (2008). PMID: 18263797 ↗
L2PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, 10. Complications
[44]
Jiménez D, Kopecna D, Tapson V et al.. “Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism.” American journal of respiratory and critical care medicine (2014). PMID: 24471575 ↗
L2PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[45]
Walsh SLF, Mackintosh JA, Calandriello L et al.. “Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography.” American journal of respiratory and critical care medicine (2022). PMID: 35696341 ↗
L3PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[46]
Becattini C, Agnelli G, Germini F et al.. “Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis.” The European respiratory journal (2014). PMID: 24603813 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[47]
Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A et al.. “Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.” The European respiratory journal (2017). PMID: 28232411 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications
[48]
Squizzato A, Galli M, Dentali F et al.. “Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review.” The European respiratory journal (2009). PMID: 19407049 ↗
L2SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[49]
Chopard R, Nielsen P, Ius F et al.. “Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: a systematic review and meta-analysis.” The European respiratory journal (2022). PMID: 35487534 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[50]
Mahé I, Carrier M, Mayeur D et al.. “Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.” The New England journal of medicine (2025). PMID: 40162636 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History
[51]
Lincoff AM, Bhasin S, Flevaris P et al.. “Cardiovascular Safety of Testosterone-Replacement Therapy.” The New England journal of medicine (2023). PMID: 37326322 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[52]
Rosenfield K, Klok FA, Piazza G et al.. “Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism.” The New England journal of medicine (2026). PMID: 41910345 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History
[53]
O'Toole RV, Stein DM, O'Hara NN et al.. “Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.” The New England journal of medicine (2023). PMID: 36652352 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History
[54]
Khorana AA, Soff GA, Kakkar AK et al.. “Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.” The New England journal of medicine (2019). PMID: 30786186 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification
[55]
Samama CM, Laporte S, Rosencher N et al.. “Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.” The New England journal of medicine (2020). PMID: 32223113 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors
[56]
Eikelboom JW, Jolly SS, Belley-Cote EP et al.. “Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.” The Lancet. Respiratory medicine (2022). PMID: 36228641 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance
[57]
Jervan Ø, Haukeland-Parker S, Gleditsch J et al.. “The Effects of Exercise Training in Patients With Persistent Dyspnea Following Pulmonary Embolism: A Randomized Controlled Trial.” Chest (2023). PMID: 37149257 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[58]
Bova C, Sanchez O, Prandoni P et al.. “Identification of intermediate-risk patients with acute symptomatic pulmonary embolism.” The European respiratory journal (2014). PMID: 24696111 ↗
L2SR_COHORTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History
[59]
Decousus H, Prandoni P, Mismetti P et al.. “Fondaparinux for the treatment of superficial-vein thrombosis in the legs.” The New England journal of medicine (2010). PMID: 20860504 ↗
L1RCTCited in: 4. Clinical Presentation
[60]
Farmakis IT, Valerio L, Barco S et al.. “Cardiopulmonary exercise testing during follow-up after acute pulmonary embolism.” The European respiratory journal (2023). PMID: 36958742 ↗
L2PROSPECTIVE_COHORTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification
[61]
Font C, Carmona-Bayonas A, Beato C et al.. “Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.” The European respiratory journal (2017). PMID: 28052954 ↗
L2PROSPECTIVE_COHORTCited in: 4. Clinical Presentation
[62]
Kline JA, Hogg MM, Courtney DM et al.. “D-dimer and exhaled CO2/O2 to detect segmental pulmonary embolism in moderate-risk patients.” American journal of respiratory and critical care medicine (2010). PMID: 20448094 ↗
L2NON_RANDOMIZED_TRIALCited in: 4. Clinical Presentation
[63]
Henzler T, Roeger S, Meyer M et al.. “Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction.” The European respiratory journal (2011). PMID: 21965223 ↗
L2NON_RANDOMIZED_TRIALCited in: 4. Clinical Presentation
[64]
Rizkallah J, Man SFP, Sin DD. “Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis.” Chest (2008). PMID: 18812453 ↗
L2SR_COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[65]
Arzt M, Luigart R, Schum C et al.. “Sleep-disordered breathing in deep vein thrombosis and acute pulmonary embolism.” The European respiratory journal (2012). PMID: 22362853 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation
[66]
Falster C, Jacobsen N, Coman KE et al.. “Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis.” Thorax (2021). PMID: 34497138 ↗
L2SR_COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[67]
Lichtenstein DA, Mezière GA. “Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol.” Chest (2008). PMID: 18403664 ↗
L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[68]
Ellison AM, Kuppermann N, Shihabuddin BS et al.. “PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study.” The Lancet. Respiratory medicine (2026). PMID: 42398511 ↗
L2CASE_SERIESCited in: 4. Clinical Presentation
[69]
Celli BR, Fabbri LM, Aaron SD et al.. “Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice.” American journal of respiratory and critical care medicine (2023). PMID: 36701677 ↗
L5NARRATIVE_REVIEWCited in: 4. Clinical Presentation
[70]
Rali PM, Criner GJ. “Submassive Pulmonary Embolism.” American journal of respiratory and critical care medicine (2018). PMID: 29672125 ↗
L5NARRATIVE_REVIEWCited in: 4. Clinical Presentation
[71]
Jiménez D, Aujesky D, Díaz G et al.. “Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism.” American journal of respiratory and critical care medicine (2010). PMID: 20110556 ↗
L2PROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[72]
Jiménez D, Bikdeli B, Barrios D et al.. “Management appropriateness and outcomes of patients with acute pulmonary embolism.” The European respiratory journal (2018). PMID: 29724918 ↗
L2PROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[73]
Nijkeuter M, Hovens MM, Davidson BL et al.. “Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review.” Chest (2006). PMID: 16424432 ↗
L2SR_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[74]
Aleva FE, Voets LWLM, Simons SO et al.. “Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A Systematic Review and Meta-analysis.” Chest (2016). PMID: 27522956 ↗
L2SR_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[75]
Roussel M, Bannelier H, Lebal S et al.. “D-Dimer thresholds for diagnosis of pulmonary embolism based on a single question: is it the most likely diagnosis? A prospective, multicentre, open-label, single-arm interventional study.” The Lancet. Respiratory medicine (2025). PMID: 41135553 ↗
L2NON_RANDOMIZED_TRIALCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[76]
Zhai Z, Wang D, Lei J et al.. “Trends in risk stratification, in-hospital management and mortality of patients with acute pulmonary embolism: an analysis from the China pUlmonary thromboembolism REgistry Study (CURES).” The European respiratory journal (2021). PMID: 33986031 ↗
L3COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[77]
Zöller B, Pirouzifard M, Memon AA et al.. “Risk of pulmonary embolism and deep venous thrombosis in patients with asthma: a nationwide case-control study from Sweden.” The European respiratory journal (2017). PMID: 28202551 ↗
L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[78]
Lega JC, Lacasse Y, Lakhal L et al.. “Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis.” Thorax (2009). PMID: 19525265 ↗
L1SR_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[79]
Wolf S, Valerio L, Kucher N et al.. “Acute pulmonary embolism in children and adolescents in the USA (2016 and 2019): a nationwide retrospective cohort study.” The Lancet. Respiratory medicine (2025). PMID: 39919780 ↗
L3RETROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[80]
Vanni S, Jiménez D, Nazerian P et al.. “Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate.” Thorax (2015). PMID: 25661114 ↗
L2PROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[81]
Liao H, Na MJ, Dikensoy O et al.. “Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases.” Respirology (Carlton, Vic.) (2008). PMID: 18197911 ↗
L3RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[82]
Kearon C, de Wit K, Parpia S et al.. “Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability.” The New England journal of medicine (2019). PMID: 31774957 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
[83]
Sanchez O, Trinquart L, Caille V et al.. “Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study.” American journal of respiratory and critical care medicine (2009). PMID: 19910608 ↗
L2PROSPECTIVE_COHORTCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
[84]
Ho KM, Rao S, Honeybul S et al.. “A Multicenter Trial of Vena Cava Filters in Severely Injured Patients.” The New England journal of medicine (2019). PMID: 31259488 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification
[85]
Lankeit M, Konstantinides S. “Is it time for home treatment of pulmonary embolism?” The European respiratory journal (2012). PMID: 22496322 ↗
L5PROSPECTIVE_COHORTCited in: 6. Severity, Staging and Risk Stratification
[86]
Hellenkamp K, Schwung J, Rossmann H et al.. “Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin.” The European respiratory journal (2015). PMID: 26493800 ↗
L2PROSPECTIVE_COHORTCited in: 6. Severity, Staging and Risk Stratification
[87]
Mulder FI, Di Nisio M, Ay C et al.. “Clinical implications of incidental venous thromboembolism in cancer patients.” The European respiratory journal (2020). PMID: 31727694 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[88]
Jiménez D, Rodríguez C, León F et al.. “Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism.” The European respiratory journal (2022). PMID: 34385269 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[89]
Ison MG, Papi A, Athan E et al.. “Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 40245915 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance
[90]
Barrios D, Durán D, Rodríguez C et al.. “Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial.” Chest (2023). PMID: 37717936 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment
[91]
Planquette B, Bertoletti L, Charles-Nelson A et al.. “Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.” Chest (2021). PMID: 34627853 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management
[92]
Castellucci LA, Chen VM, Kovacs MJ et al.. “Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.” The New England journal of medicine (2026). PMID: 41812192 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
[93]
Meyer G, Vicaut E, Danays T et al.. “Fibrinolysis for patients with intermediate-risk pulmonary embolism.” The New England journal of medicine (2014). PMID: 24716681 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History
[94]
Agnelli G, Becattini C, Meyer G et al.. “Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.” The New England journal of medicine (2020). PMID: 32223112 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[95]
Büller HR, Décousus H, Grosso MA et al.. “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.” The New England journal of medicine (2013). PMID: 23991658 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[96]
Büller HR, Prins MH, Lensin AW et al.. “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.” The New England journal of medicine (2012). PMID: 22449293 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue
[97]
Rosovsky RP, Grodzin C, Channick R et al.. “Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium.” Chest (2020). PMID: 32861692 ↗
L1GUIDELINECited in: 8. Long-term and Definitive Management
[98]
Girard P, Decousus M, Laporte S et al.. “Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy.” American journal of respiratory and critical care medicine (2001). PMID: 11587992 ↗
L2RCTCited in: History and Evolution of Treatment
[99]
Izbicki G, Bairey O, Shitrit D et al.. “Increased thromboembolic events after lung transplantation.” Chest (2006). PMID: 16478860 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[100]
Chieng H, Saha B, Foulke L et al.. “A 24-Year-Old Man With Dyspnea and a Broken Left Femur.” Chest (2022). PMID: 35396056 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[101]
Egan T, Blackwell J, Birchard K et al.. “Assessment of Lungs for Transplant Recovered from Uncontrolled Donation after Circulatory Determination of Death Donors.” Annals of the American Thoracic Society (2017). PMID: 28945476 ↗
L2NON_RANDOMIZED_TRIALCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[102]
Lankeit M, Dellas C, Panzenböck A et al.. “Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2008). PMID: 18256058 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[103]
Bax S, Jacob J, Ahmed R et al.. “Right Ventricular to Left Ventricular Ratio at CT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease.” Chest (2019). PMID: 31351047 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[104]
Skoro-Sajer N, Marta G, Gerges C et al.. “Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy.” Thorax (2013). PMID: 24052543 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[105]
Neri G, Mazza G, Mastrangelo H et al.. “Safety of Invasive Procedures During Adult Extracorporeal Membrane Oxygenation: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42355959 ↗
L2SR_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[106]
Liang G, Peng H, Li Y. “Clinical efficacy and safety of robotic-assisted thoracic surgery after neoadjuvant therapy in non-small cell lung cancer: a systematic review and meta-analysis.” Updates in surgery (2026). PMID: 41729427 ↗
L2SR_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[107]
Hosokawa K, Masaki K, Hirose M et al.. “Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42315026 ↗
L2PROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[108]
Rangwala HS, Rangwala BS, Alotaibi M et al.. “Clinical Outcomes with High- versus Low-Dose Tranexamic Acid Infusion in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.” The Thoracic and cardiovascular surgeon (2025). PMID: 39842460 ↗
L1SR_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[109]
Madeka I, Noueihed K, Woodroof J et al.. “Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection.” JAMA network open (2026). PMID: 42223938 ↗
L3RETROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[110]
Truitt BA, Kasi AS, Kamat PP et al.. “Cryoextraction via flexible bronchoscopy in children with tracheobronchial obstruction.” Pediatric pulmonology (2023). PMID: 37350368 ↗
L4COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[111]
. “[Expert consensus on operational procedures for bronchial artery embolization in the treatment of hemoptysis].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2025). PMID: 40300866 ↗
L5GUIDELINECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[112]
Naser-Tavakolian K, Sajan A, Krishnasamy VP et al.. “Outcomes of inferior vena cava filtration in lung transplant recipients.” Frontiers in radiology (2026). PMID: 41947864 ↗
L4RETROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[113]
Kim NT, Miyashita Y, Kaihou T et al.. “Risk factors and perioperative complications associated with deep venous thrombosis and pulmonary embolism after lung transplantation.” Journal of thoracic disease (2025). PMID: 41376962 ↗
L3RETROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[114]
Kamar A, Miyashita Y, Kaiho T et al.. “Risk factors and clinical outcomes of serum Aspergillus galactomannan antigen (AGA) positivity in lung transplantation.” Journal of thoracic disease (2025). PMID: 41229833 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[115]
Liu J, Bao B, Zhang T et al.. “Comparative analysis of the clinical characteristics of severe Mycoplasma pneumoniae pneumonia and severe bacterial pneumonia in children.” BMC pediatrics (2025). PMID: 40448048 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[116]
Li H, Li SD, Jiang QC et al.. “Case Report: Early diaphragmatic plication for combined phrenic and recurrent laryngeal nerve injury after VATS thymectomy.” Frontiers in medicine (2026). PMID: 42454123 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[117]
Williams AM, Kathawate RG, Khosravi R et al.. “Utilizing lung donors with recent massive pulmonary emboli and chronic thromboembolic disease for transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2024). PMID: 39447751 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[118]
Altun I, Zhao Y, Basnet S et al.. “The Role of Mechanical Thrombectomy for Acute Massive Pulmonary Embolism in a Patient With Unilateral Lung Transplant and Atrial Septal Defect.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023). PMID: 37776207 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
[119]
Morris TA, Castrejon S, Devendra G et al.. “No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.” Chest (2007). PMID: 17646239 ↗
L1SR_MA_RCTCited in: 10. Complications
[120]
Shivakumar S, Matino D, Zukor D et al.. “Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty.” The New England journal of medicine (2026). PMID: 42437501 ↗
L1RCTCited in: 10. Complications
[121]
Anderson DR, Dunbar M, Murnaghan J et al.. “Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.” The New England journal of medicine (2018). PMID: 29466159 ↗
L1RCTCited in: 10. Complications
[122]
Myles PS, Smith JA, Forbes A et al.. “Stopping vs. Continuing Aspirin before Coronary Artery Surgery.” The New England journal of medicine (2016). PMID: 26933848 ↗
L1RCTCited in: 10. Complications, 12. Special Populations & Pregnancy
[123]
Myles PS, Smith JA, Forbes A et al.. “Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.” The New England journal of medicine (2016). PMID: 27774838 ↗
L1RCTCited in: 10. Complications, 12. Special Populations & Pregnancy
[124]
Goldhaber SZ, Leizorovicz A, Kakkar AK et al.. “Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.” The New England journal of medicine (2011). PMID: 22077144 ↗
L1RCTCited in: 10. Complications
[125]
Planquette B, Sanchez O, Marsh JJ et al.. “Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.” The European respiratory journal (2018). PMID: 30337447 ↗
L2PROSPECTIVE_COHORTCited in: 10. Complications
[126]
Martín de Miguel I, Jiménez López-Guarch C, Segura de La Cal T et al.. “Chronic Thromboembolic Pulmonary Disease With Exercise Pulmonary Hypertension: A Noninvasive Model to Predict Exercise Hemodynamics.” Chest (2025). PMID: 41238055 ↗
L2PROSPECTIVE_COHORTCited in: 10. Complications
[127]
George PM, Barratt SL, Condliffe R et al.. “Respiratory follow-up of patients with COVID-19 pneumonia.” Thorax (2020). PMID: 32839287 ↗
L5SR_COHORTCited in: 10. Complications
[128]
Inparaj S, Buckingham M, Oakley L et al.. “Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis.” Thorax (2020). PMID: 32345690 ↗
L1SR_COHORTCited in: 10. Complications, 12. Special Populations & Pregnancy
[129]
Zondag W, Kooiman J, Klok FA et al.. “Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis.” The European respiratory journal (2012). PMID: 23100493 ↗
L1SR_COHORTCited in: 11. Prognosis and Natural History
[130]
Blondon M, Casini A, Hoppe KK et al.. “Risks of Venous Thromboembolism After Cesarean Sections: A Meta-Analysis.” Chest (2016). PMID: 27262227 ↗
L1SR_COHORTCited in: 12. Special Populations & Pregnancy
[131]
Davies CW, Wimperis J, Green ES et al.. “Early discharge of patients with pulmonary embolism: a two-phase observational study.” The European respiratory journal (2007). PMID: 17567672 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy
[132]
Tafelmeier M, Luft L, Zistler E et al.. “Central Sleep Apnea Predicts Pulmonary Complications After Cardiac Surgery.” Chest (2020). PMID: 32798522 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy
[133]
Sheen JJ, Haramati LB, Natenzon A et al.. “Performance of Low-Dose Perfusion Scintigraphy and CT Pulmonary Angiography for Pulmonary Embolism in Pregnancy.” Chest (2017). PMID: 28823756 ↗
L2RETROSPECTIVE_COHORTCited in: 12. Special Populations & Pregnancy
[134]
Wiesen MH, Blaich C, Müller C et al.. “The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk.” Chest (2016). PMID: 27396794 ↗
L4CASE_SERIESCited in: 12. Special Populations & Pregnancy
[135]
Kaeberich A, Seeber V, Jiménez D et al.. “Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism.” The European respiratory journal (2015). PMID: 25614162 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy
[136]
Middleton P, Shepherd E, Gomersall JC. “Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.” The Cochrane database of systematic reviews (2021). PMID: 33779986 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[137]
Kolkailah AA, Abdelghaffar B, Elshafeey F et al.. “Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients.” The Cochrane database of systematic reviews (2024). PMID: 39629741 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[138]
Matar CF, Kahale LA, Hakoum MB et al.. “Anticoagulation for perioperative thromboprophylaxis in people with cancer.” The Cochrane database of systematic reviews (2018). PMID: 29993117 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[139]
Perel P, Ker K, Morales Uribe CH et al.. “Tranexamic acid for reducing mortality in emergency and urgent surgery.” The Cochrane database of systematic reviews (2013). PMID: 23440847 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[140]
Akl EA, Kahale L, Sperati F et al.. “Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.” The Cochrane database of systematic reviews (2014). PMID: 24966161 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[141]
Akl EA, Labedi N, Terrenato I et al.. “Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.” The Cochrane database of systematic reviews (2011). PMID: 22071865 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[142]
Okusanya BO, Oladapo OT. “Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy.” The Cochrane database of systematic reviews (2016). PMID: 28005272 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[143]
Bain E, Wilson A, Tooher R et al.. “Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.” The Cochrane database of systematic reviews (2014). PMID: 24519568 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy
[144]
Wiener RS, Ouellette DR, Diamond E et al.. “An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine.” Chest (2014). PMID: 24889436 ↗
L5GUIDELINECited in: 13. Prevention, Screening & Surveillance
[145]
Reddy SA, Newman J, Leavy OC et al.. “Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies.” The European respiratory journal (2024). PMID: 39060016 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance
[146]
Hajduk B, Tomkowski WZ, Malek G et al.. “Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: a prospective, observational cohort study.” Chest (2009). PMID: 19880907 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance
[147]
Ghincea A, Ryu C, Herzog EL. “An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report.” Chest (2022). PMID: 35131075 ↗
L4CASE_SERIESCited in: 13. Prevention, Screening & Surveillance
[148]
Li L, Sun T, Zhang P et al.. “Statins for primary prevention of venous thromboembolism.” The Cochrane database of systematic reviews (2011). PMID: 22161421 ↗
L1SR_MA_RCTCited in: 13. Prevention, Screening & Surveillance
[149]
Wang Z, Zhang P, Tian J et al.. “Statins for the primary prevention of venous thromboembolism.” The Cochrane database of systematic reviews (2024). PMID: 39498835 ↗
L1SR_MA_RCTCited in: 13. Prevention, Screening & Surveillance
[150]
Li L, Zhang P, Tian JH et al.. “Statins for primary prevention of venous thromboembolism.” The Cochrane database of systematic reviews (2014). PMID: 25518837 ↗
L1SR_MA_RCTCited in: 13. Prevention, Screening & Surveillance
[151]
Greinacher A, Thiele T, Warkentin TE et al.. “Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.” The New England journal of medicine (2021). PMID: 33835769 ↗
L4CASE_SERIESCited in: 13. Prevention, Screening & Surveillance
[152]
Carlbom DJ, Davidson BL. “Pulmonary embolism in the critically ill.” Chest (2007). PMID: 17625093 ↗
L5NARRATIVE_REVIEWCited in: 13. Prevention, Screening & Surveillance
[153]
George MG, Schieb LJ, Ayala C et al.. “Pulmonary hypertension surveillance: United States, 2001 to 2010.” Chest (2014). PMID: 24700091 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[154]
Hüneburg R, van Bokhorst QNE, Pellisé M et al.. “Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 42462747 ↗
L1RCTCited in: 13. Prevention, Screening & Surveillance
[155]
Barda N, Dagan N, Ben-Shlomo Y et al.. “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.” The New England journal of medicine (2021). PMID: 34432976 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance
[156]
Zhang X, Sun S, Fan X et al.. “Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database.” Frontiers in cardiovascular medicine (2026). PMID: 41756513 ↗
L1SR_COHORTCited in: 13. Prevention, Screening & Surveillance
[157]
Kim J, Kim TH. “Extended Postoperative Risk of Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Cohort Study.” Spine (2026). PMID: 42308362 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance
[158]
Yang S, Li G, Li Y et al.. “In-hospital deep vein thrombosis after tibial plateau fractures: incidence, laterality/anatomy, and risk factors in a multicenter retrospective cohort of 3366 patients.” Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology (2026). PMID: 41886203 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance
[159]
Holstein RA, Meyer CH, Herrmann O et al.. “Incidence and Risk Factors for Venous Thromboembolism in Hemodynamically Unstable Pelvic Fractures.” The Journal of surgical research (2026). PMID: 41650792 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance
[160]
Aljameie M, Ahmed Shimal A, Mahmoud MH et al.. “Comparative safety and effectiveness of midline catheters vs. peripherally inserted central catheters: a systematic review and meta-analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42609201 ↗
L1aCited in: 6. Severity, Staging and Risk Stratification
[161]
Simanjuntak AM, Wijayanto FP, Tristan CD et al.. “Catheter-directed thrombolysis versus anticoagulation for intermediate-risk and high-risk pulmonary embolism: a systematic review and meta-analysis.” Open heart (2026). PMID: 42580844 ↗
L1aCited in: 6. Severity, Staging and Risk Stratification
[162]
Schultz J, Egholm G, Poulsen MK et al.. “Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2026). PMID: 42610339 ↗
L1bCited in: 6. Severity, Staging and Risk Stratification
[163]
Ranty M, Tromeur C, Pronost P et al.. “Association between Pulmonary Vascular Obstruction Phenotype and Pulmonary Embolism Recurrence: Results from the PADIS-PE Study.” Thrombosis and haemostasis (2026). PMID: 42580750 ↗
L1bCited in: 6. Severity, Staging and Risk Stratification
[164]
Huang C, Li S, He J. “Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Thrombosis: An Indication-Stratified Systematic Review and Meta-Analysis of Treatment and Postoperative Prophylaxis.” Cardiovascular drugs and therapy (2026). PMID: 42622790 ↗
L2aCited in: 6. Severity, Staging and Risk Stratification
[165]
Adjei E, Stokes JW, Dereshgi AT et al.. “Is systemic anticoagulation necessary during intraoperative venoarterial extracorporeal membrane oxygenation for bilateral lung transplantation? A feasibility study comparing zero-, low-, and high-intensity heparin strategies.” JTCVS open (2026). PMID: 42604300 ↗
L4Cited in: 6. Severity, Staging and Risk Stratification
[166]
Thorman IB, Sacknovitz A, Goyal A et al.. “Gabapentin and cognitive impairment after traumatic brain injury: A multinational cohort of 49,925 patients.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 42595621 ↗
L4Cited in: 6. Severity, Staging and Risk Stratification
[167]
Eichinger S, Eischer L, Kaider A et al.. “Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study.” Blood (2026). PMID: 42574295 ↗
L4Cited in: 6. Severity, Staging and Risk Stratification
[168]
Tummala S, Mittal MM, Sambandam SN et al.. “Differential complication risks in diabetic and non-diabetic geriatric patients following distal femur fracture surgery.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026). PMID: 42550286 ↗
L2bCited in: 6. Severity, Staging and Risk Stratification
[169]
Cimini LA, Klok FA, Carrier M et al.. “Risk-of-bias assessment in prognostic cohort studies: a methodological comparison study of structured appraisal tools in acute pulmonary embolism research.” BMJ open (2026). PMID: 42562580 ↗
L2bCited in: 6. Severity, Staging and Risk Stratification
[170]
Ho CYA, Chan YC, Cheung GC. “Association of clinical frailty with the development and adverse outcomes of venous diseases: A systematic review and meta-analysis.” Phlebology (2026). PMID: 42613745 ↗
L2aCited in: 6. Severity, Staging and Risk Stratification
[171]
Al Yami MS. “Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42610841 ↗
L2aCited in: 6. Severity, Staging and Risk Stratification
[172]
Liao CC, Chang CC, Yeh CC et al.. “The Optimal Timing for Patients With Acute Myocardial Infarction to Safely Undergo Elective Non-Cardiac Surgery: A Retrospective Cohort Study.” Mayo Clinic proceedings (2026). PMID: 42624286 ↗
L3bCited in: 6. Severity, Staging and Risk Stratification
[173]
Dhalla Z, Nunn K, Teoh V et al.. “Impact of chronic beta-blocker versus renin-angiotensin inhibitor use on outcomes after blunt pelvic trauma.” Surgery (2026). PMID: 42618398 ↗
L3bCited in: 6. Severity, Staging and Risk Stratification
[174]
Elias LH, Allen M, Adeleye O et al.. “Ninety-day venous thromboembolism incidence and associated risk factors after total and reverse shoulder arthroplasty: a national database analysis.” Journal of shoulder and elbow arthroplasty (2026). PMID: 42604140 ↗
L4Cited in: 6. Severity, Staging and Risk Stratification
[175]
Yin C, Qiang Y, Mei Z et al.. “Association of awake prone positioning with clinical outcomes in severe immune checkpoint inhibitor-associated pneumonitis with acute hypoxemic respiratory failure: a propensity-matched retrospective cohort study.” Frontiers in medicine (2026). PMID: 42602213 ↗
L3bCited in: 6. Severity, Staging and Risk Stratification
[176]
Pop C, Manea V, Pop LL et al.. “Cancer-Associated Pulmonary Embolism in Contemporary Clinical Practice: Clinical Severity, Incidental Detection, and Early Outcomes in a Real-World Cohort.” Journal of clinical medicine (2026). PMID: 42590194 ↗
L3bCited in: 6. Severity, Staging and Risk Stratification
[177]
Austin E, Reichard A, Muck P et al.. “Adding artificial intelligence to the pulmonary embolism response team improves time to diagnosis and treatment of pulmonary embolism.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 42570761 ↗
L4Cited in: 6. Severity, Staging and Risk Stratification
[178]
Alhuneafat L, Obeidat O, Mohammed D et al.. “Five-year cardiovascular outcomes across hypertensive disorders of pregnancy subtypes: a propensity-matched analysis.” Frontiers in cardiovascular medicine (2026). PMID: 42568675 ↗
L3bCited in: 6. Severity, Staging and Risk Stratification
[179]
Khoury G, Manon J, Buteau P et al.. “Immediate weight-bearing for pelvic ring fractures: A case-control study based on a retrospective monocentric series of 163 patients.” Orthopaedics & traumatology, surgery & research : OTSR (2026). PMID: 42551743 ↗
L3bCited in: 6. Severity, Staging and Risk Stratification
[180]
Page A, Mares K, McCormack C. “Safety of exercise after pulmonary endarterectomy: a systematic review.” ERJ open research (2026). PMID: 42577748 ↗
L1aCited in: 7. Acute Management and Exacerbation Rescue
[181]
Shen M, Tan X, Xianyu Y et al.. “Developing and evaluating an in situ, simulated emergency training course for nurses with low seniority.” BMC medical education (2026). PMID: 42533330 ↗
L1bCited in: 7. Acute Management and Exacerbation Rescue
[182]
Illerhaus G, Ferreri AJM, Wendler J et al.. “High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.” Lancet (London, England) (2026). PMID: 42486133 ↗
L1bCited in: 7. Acute Management and Exacerbation Rescue
[183]
Akerboom B, Martens ESL, Stals MAM et al.. “YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.” JAMA (2026). PMID: 42437322 ↗
L1bCited in: 7. Acute Management and Exacerbation Rescue
[184]
Li C, Zeng N, Wang F et al.. “Conscious sedation as a potential optimal anesthetic regimen for endoscopic retrograde cholangiopancreatography in elderly frail patients: A prospective, single-blind, randomized controlled trial.” Saudi journal of anaesthesia (2026). PMID: 42553904 ↗
L1bCited in: 7. Acute Management and Exacerbation Rescue
[185]
Parmar T, Adio A, Daher M et al.. “Intravenous versus oral tranexamic acid in shoulder arthroplasty.” Archives of orthopaedic and trauma surgery (2026). PMID: 42472728 ↗
L2bCited in: 7. Acute Management and Exacerbation Rescue
[186]
Liu X, Fan H, Hai Y et al.. “Diagnostic Validation of PERC and Resource Utilization in Suspected Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42541393 ↗
L2aCited in: 7. Acute Management and Exacerbation Rescue
[187]
Lee S, Thomas C, Posso AN et al.. “Is microsurgical autologous breast reconstruction safe in patients with a history of venous thromboembolism? A retrospective cohort study of 14,309 patients.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2026). PMID: 42600541 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[188]
González-Hermosillo LM, Cueto-Robledo G, Gaytan-Cervantes J et al.. “Methylation in the TAC1 Gene Promoter Is Associated with the Transition from Acute Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension.” International journal of molecular sciences (2026). PMID: 42589567 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[189]
Parmar T, Fiandeiro M, Daher M et al.. “Perioperative antihypertensive medication use is associated with no antifibrotic benefit but higher complications and revision rates following shoulder arthroplasty.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026). PMID: 42542466 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[190]
Bloom JE, Zilinyi R, Mahony E et al.. “Incidence and outcomes of emergency medical service treated pulmonary embolism in Victoria, Australia: A population-based cohort study.” Annals of epidemiology (2026). PMID: 42526730 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[191]
Azulay AA, Stein M, Tabo LY et al.. “High-velocity gunshot chest trauma: tailoring patient care through insights from a mass casualty experience.” European journal of trauma and emergency surgery : official publication of the European Trauma Society (2026). PMID: 42525108 ↗
L4Cited in: 7. Acute Management and Exacerbation Rescue
[192]
Divya A, Dalal N, Nandavaram S et al.. “Sex-based differences in long-term respiratory and pulmonary vascular outcomes after acute pulmonary embolism: A propensity-matched analysis of 795,338 patients.” Respiratory medicine (2026). PMID: 42456831 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[193]
Tang M, Zhao J, Tong R. “Successful management of life-threatening acute pulmonary embolism during anesthesia induction for comminuted intertrochanteric fracture surgery: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 42440677 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[194]
Stubblefield WB, Barclay J, Wrenn JO et al.. “Initiation of an emergency department discharge pathway for low-risk patients with venous thromboembolism: Factors impact real-world practice.” Vascular medicine (London, England) (2026). PMID: 42405533 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[195]
Bittermann C, Gicquel E, Douillet D et al.. “Reassessment strategy to reduce chest imaging in patients with suspected pulmonary embolism and elevated D-dimer: an exploratory cohort study.” Research and practice in thrombosis and haemostasis (2026). PMID: 42592082 ↗
L4Cited in: 7. Acute Management and Exacerbation Rescue
[196]
Zhuang H, Chen X, Zhang Z et al.. “Conical Mesh-Disc Catheter-Directed Mechanical Thrombectomy for Acute Pulmonary Embolism: A Nationwide Prospective, Multicenter, Single-Arm Study.” Annals of vascular surgery (2026). PMID: 42526750 ↗
L2bCited in: 7. Acute Management and Exacerbation Rescue
[197]
Korzeniewski SJ, Kabrhel C, Courtney DM et al.. “Laboratory virus test positivity is not associated with increased venous thromboembolism risk among patients presenting with acute respiratory illnesses to U.S. emergency departments.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42586320 ↗
L3bCited in: 7. Acute Management and Exacerbation Rescue
[198]
Yoshimoto Y, Takegami Y, Asai S et al.. “Clinical Outcomes and Adverse Events of Continuous Local Antibiotic Perfusion for Orthopedic Infections: A Multi-Category Retrospective Study.” Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association (2026). PMID: 42618354 ↗
L4Cited in: 7. Acute Management and Exacerbation Rescue
[199]
Potere N, Bertù L, Bucherini E et al.. “Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a post-hoc analysis of the RIDTS trial.” Haematologica (2026). PMID: 42389836 ↗
L1bCited in: 8. Long-term and Definitive Management
[200]
Goryachok M, Liu J, Benjamin T et al.. “A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.” NEJM evidence (2026). PMID: 42334298 ↗
L1bCited in: 8. Long-term and Definitive Management
[201]
Li Z, Hu J, Chen J et al.. “Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42296979 ↗
L1bCited in: 8. Long-term and Definitive Management
[202]
Calabrò RS, Calderone A, Arcadi FA et al.. “Early-event pathways to 6-month death or dependency after ischemic stroke: Secondary analysis of the international stroke trial.” Journal of the neurological sciences (2026). PMID: 42263448 ↗
L1bCited in: 8. Long-term and Definitive Management
[203]
Ibba L, Di Giulio S, Malagoli P et al.. “Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.” Dermatology and therapy (2026). PMID: 42262460 ↗
L1bCited in: 8. Long-term and Definitive Management
[204]
Camporese G, Bernardi E, Bortoluzzi C et al.. “Mesoglycan for long-term secondary prevention in patients with superficial vein thrombosis (METRO): a multicentre randomised clinical trial in Italy.” EClinicalMedicine (2026). PMID: 42534458 ↗
L2bCited in: 8. Long-term and Definitive Management
[205]
Vosoughi F, Ramezanpour MR, Hashemi FS et al.. “Outcomes of Total Knee Arthroplasty in Patients Receiving Chronic Antithrombotic Therapy: A Systematic Review.” The Journal of arthroplasty (2026). PMID: 42546786 ↗
L2aCited in: 8. Long-term and Definitive Management
[206]
Sheikh H, Singh A, Smith C et al.. “Association of advanced therapies for intermediate- to high-risk pulmonary embolism with improved right ventricular function on outpatient follow-up among survivors.” Frontiers in cardiovascular medicine (2026). PMID: 42358637 ↗
L2bCited in: 8. Long-term and Definitive Management
[207]
Ryde HV, Reinert MS, Hartwell D et al.. “Endometriosis and long-term risk of venous thromboembolism: a Danish nationwide study.” European heart journal (2026). PMID: 42568051 ↗
L3bCited in: 8. Long-term and Definitive Management
[208]
Khan YY, Alzahrani AA, Alghamdi RS et al.. “Efficacy and safety of prehospital whole blood resuscitation in traumatic haemorrhagic shock a systematic review and meta-analysis.” The American journal of emergency medicine (2026). PMID: 42526297 ↗
L1aCited in: 10. Complications
[209]
Humenberger M, Langenecker S, Antoni A et al.. “[Prevention of venous thromboembolism in orthopaedics and traumatology: Austrian interdisciplinary consensus statement 2026].” Wiener klinische Wochenschrift (2026). PMID: 42550214 ↗
L1cCited in: 10. Complications
[210]
Zhang F, Chen J, Li T et al.. “Development and validation of a nomogram to predict the risk of deep venous thrombosis after hip replacement in elderly patients with femoral neck fracture.” Frontiers in surgery (2026). PMID: 42597463 ↗
L1bCited in: 10. Complications
[211]
Zou H, Zhao Y, Ji Z et al.. “SWAM Mechanical Thrombectomy System versus AngioJet Rheolytic Thrombectomy System for Acute Lower Extremity Deep Vein Thrombosis: A Prospective, Randomized, Single-Center Study.” Annals of vascular surgery (2026). PMID: 42575266 ↗
L1bCited in: 10. Complications
[212]
Pinto TF, Santoro A, de Oliveira ALG et al.. “Risk of Post-acute Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42628715 ↗
L2aCited in: 10. Complications
[213]
Holdorf F, Soemmer C, Vitkos E et al.. “Pulmonary embolism after radial forearm free flap reconstruction for oral squamous cell carcinoma: a multicenter retrospective cohort study.” Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery (2026). PMID: 42546470 ↗
L2bCited in: 10. Complications
[214]
Brindl N, Chandrakumaran K, Shah N et al.. “Deep vein thrombosis and pulmonary embolism following cytoreductive surgery and HIPEC for PMP of appendiceal origin.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42566936 ↗
L3bCited in: 10. Complications